Scholarlink

<p>As a PI3K enzyme inhibitor, quercetin is of great potential in cancer treatment. Development of a drug carrier for quercetin with higher loading capacity and controlled release performance is helpful to implement targeted and precise treatment and to improve the drug efficacy. For this purpose, a molecularly imprinted drug carrier for quercetin (MIDC-Q) was prepared successfully by surface imprinting on a ZIF-67@oc-poss@p-VPBA matrix using para-vinylphenylboronic acid (p-VPBA), N-isopropylacrylamide (NIPAAM), and acrylamide (AAM) as complex functional monomers and ethylene glycol dimethacrylate (EGDMA) as the cross-linker. Optimization of preparation conditions was performed by using an L<sub>9</sub>(<sub>3</sub><sup>4</sup>) orthogonal factor design method, and structural characterization for the carrier was done by Fourier Transform infrared spectroscopy (FTIR), Scanning Electron Microscope (SEM), X-Ray Diffraction (XRD), X-ray Photoelectron Spectroscopy (XPS), and Brunauer-Emmet-Teller (BET) analysis. The carrier MIDC-Q10 obtained under the optimized conditions has been proven to have a higher loading capacity (98.65&#xa0;mg g⁻¹) toward the drug quercetin and possesses two main types of binding sites. When this quercetin-loaded carrier was used to perform a release behavior test in vitro, the release rate for quercetin could be controlled by adjusting media pH value, temperature, and/or ionic strength. The carrier showed significantly reduced release dynamics at 303&#xa0;K in pH 7.2 media, needing about 84&#xa0;h to reach 94.58% cumulative release. This controlled release behavior for this imprinted drug carrier might result from such chemical interactions as covalent bond, hydrogen bond, coordination interactions, and even ionic bonds between the molecular imprinting sites and the target molecules. The present work developed a novel and promising drug carrier for quercetin with controlled release performance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis of a novel molecularly imprinted drug carrier for quercetin and its controlled release behavior

  • 期刊论文

  • 发表日期：

    2026年3月10日

查看全文
  • Chengcheng Yang,
  • Wentao Tan,
  • Junxi Wu,
  • Yizhen Lu,
  • Jinge Zhu,
  • Xianyu Guo,
  • Ling Wang,
  • Fengrui Yang,
  • Hui Li

摘要

As a PI3K enzyme inhibitor, quercetin is of great potential in cancer treatment. Development of a drug carrier for quercetin with higher loading capacity and controlled release performance is helpful to implement targeted and precise treatment and to improve the drug efficacy. For this purpose, a molecularly imprinted drug carrier for quercetin (MIDC-Q) was prepared successfully by surface imprinting on a ZIF-67@oc-poss@p-VPBA matrix using para-vinylphenylboronic acid (p-VPBA), N-isopropylacrylamide (NIPAAM), and acrylamide (AAM) as complex functional monomers and ethylene glycol dimethacrylate (EGDMA) as the cross-linker. Optimization of preparation conditions was performed by using an L9(34) orthogonal factor design method, and structural characterization for the carrier was done by Fourier Transform infrared spectroscopy (FTIR), Scanning Electron Microscope (SEM), X-Ray Diffraction (XRD), X-ray Photoelectron Spectroscopy (XPS), and Brunauer-Emmet-Teller (BET) analysis. The carrier MIDC-Q10 obtained under the optimized conditions has been proven to have a higher loading capacity (98.65 mg g⁻¹) toward the drug quercetin and possesses two main types of binding sites. When this quercetin-loaded carrier was used to perform a release behavior test in vitro, the release rate for quercetin could be controlled by adjusting media pH value, temperature, and/or ionic strength. The carrier showed significantly reduced release dynamics at 303 K in pH 7.2 media, needing about 84 h to reach 94.58% cumulative release. This controlled release behavior for this imprinted drug carrier might result from such chemical interactions as covalent bond, hydrogen bond, coordination interactions, and even ionic bonds between the molecular imprinting sites and the target molecules. The present work developed a novel and promising drug carrier for quercetin with controlled release performance.